

TRK FUSION CANCER

GENOMICS AND CANCER

ITRK3) NTRKI

NTRK3





The Role of Genes in Cancer

> Damage or changes to our genes can cause cancer cells to grow and eventually form a tumor¹

Looking Deeper Into the Cause

▶ The science of understanding genes and how they relate to diseases is called genomics^{2,3}

Precision Medicine

Precision medicine (also called personalized medicine) aims to prevent, diagnose, and treat disease based on a person's unique health profile, which includes their genomics^{2,4-6}

Genomic Cancer Testing Versus Genetic Testing

- ▶ Genomic cancer testing is a special kind of testing to find out which gene changes may be triggering the cancer. It can help doctors match patients to an appropriate treatment or clinical trial^{3,7}
- Genetic testing looks at a person's unique genetic profile (which is passed down from parents to child) to understand their inherited risk for getting cancer⁸

References: 1. National Cancer Institute. https://www.cancer.gov/about-cancer/causes-prevention/genetics. Accessed April 1, 2019. 2. National Institute of Health. https://ghr.nlm.nih.gov/primer/precisionmedicine/definition. Published January 15, 2019. Accessed April 1, 2019. 3. Vaishnavi A, Le AT, Doebele RC. Cancer Discov. 2015;5(1):25-34. 4. Verma M. J Pers Med. 2012;2:1-14. 5. Boland GM, Piha-Paul SA, Subbiah V, et al. Oncotarget. 2015;6(24):20099-20110. 6. Yates LR, Seoane J, Le Tourneau C, et al. Ann Oncol. 2018;29(1):30-35. 7. Foundation Medicine. https://www.foundationmedicine.com/genomic-testing. Accessed March 28, 2019. 8. American Cancer Society. https://www.cancer.org/cancer/cancer-causes/genetics/understanding-genetic-testing-for-cancer.html. Accessed May 17, 2019.

PRECISION MEDICINE USES THE UNIQUE PROFILE OF A TUMOR TO DEFINE YOUR TREATMENT JOURNEY¹⁻³

NTRK3

Traditional cancer diagnosis^{4,5}

Cancer diagnosis using precision medicine^{1,4}

Initial exam

Your doctor will

and determine

what tests are

necessary⁵

discuss your health

ai exam

Blood tests are usually ordered, since they can detect substances that may be linked with cancer⁵

Lab tests

X-rays, ultrasound, CT scans, and MRIs are often used to help see inside your body⁵

Imaging tests

Your doctor might also want to take a tissue sample to examine it more closely⁵

Biopsy +

pathology

A tissue or blood sample is tested to learn which genomic alteration may be driving the cancer^{6,7}

Molecular/

genomic

profiling

Common Factors Influencing Treatment Selection

- Cancer stage
- > Tumor characteristics
- > Other medical conditions
- > Patient preference
- Molecular/genomic characteristics

References: 1. Verma M. J Pers Med. 2012;2:1-14. 2. Boland GM, Piha-Paul SA, Subbiah V, et al. Oncotarget. 2015;6(24):20099-20110. 3. Yates LR, Seoane J, Le Tourneau C, et al. Ann Oncol. 2018;29(1):30-35. 4. American Cancer Society. https://www.cancer.org/cancer/non-small-cell-lung-cancer/detection-diagnosis-staging.html. Accessed June 5, 2019. 5. National Cancer Institute. https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis. Published March 9, 2015. Accessed June 5, 2019. 6. American Cancer Society. https://www.cancer.org/cancer/cancer-causes/genetics/genes-and-cancer/genes-in-cancer-diagnosis-and-treatment.html. Accessed June 5, 2019. 7. Foundation Medicine. https://www.foundationmedicine.com/genomic-testing. Accessed March 28, 2019.

DIAGNOSING AND TREATING CANCER WITH GENOMIC PROFILING

NTRK3

NTRK1

NTRK3



- Genomic profiling requires specialized testing (called genomic cancer testing) to find changes known as genomic alterations. Some of these genomic alterations can help doctors make treatment decisions¹
- Many patients who get genomic profiling may discover they have a genomic alteration that can be matched to an approved treatment or clinical trial²⁻⁴

Normal genes (without alterations) provide instructions on how to make proteins and other molecules needed for the body to function properly⁵

NTRK gene fusion is a genomic alteration that can help doctors make treatment decisions.^{1,6}

References: 1. Vaishnavi A, Le AT, Doebele RC. Cancer Discov. 2015;5(1):25-34. 2. Boland GM, Piha-Paul SA, Subbiah V, et al. Oncotarget. 2015;6(24):20099-20110. 3. Massard C, Michiels S, Ferté C, et al. Cancer Discov. 2017;7(6):586-595. 4. Harris MH, DuBois SG, Glade Bender JL, et al. JAMA Oncol. 2016;2(5):608-615. 5. National Institutes of Health. https://ghr.nlm.nih.gov/primer/howgeneswork/makingprotein. Accessed June 26, 2019. 6. Amatu A, Sartore-Bianchi A, Siena S. ESMO Open. 2016;1(2):e000023.


HOW GENOMIC CANCER TESTING CAN UNCOVER NTRK GENE FUSIONS AND OTHER GENOMIC ALTERATIONS



- ▶ Genomic cancer testing lets us look closer at the genes that make up a tumor¹
- Using a tissue or blood sample, a lab pathologist can identify genomic alterations that may be causing cancer¹
- ➤ This process can identify abnormalities, such as *NTRK* gene fusions, that may be matched with approved or investigational treatments^{1,2}
- Not all genomic alterations are treatable. It is important to talk with your doctor about the results of your test and if you are eligible for any approved treatments

The only way to find NTRK gene fusion is to properly test for it.3

- > TRK fusion cancer is a type of cancer caused by a change to one of our genes, called NTRK. This change is called NTRK gene fusion 1-3
- > NTRK gene fusion occurs when an NTRK gene joins together, or fuses, with a different gene. This creates and activates TRK fusion proteins¹⁻³
- ▶ These proteins can cause cancer cells to multiply and form a tumor¹⁻³



TRK FUSION CANCER CAN OCCUR IN DIFFERENT TUMOR TYPES¹⁻³

NTRK3

NTRK1

NTRK3


- > TRK fusion cancer is caused by NTRK gene fusion1
- > NTRK gene fusion can occur in many different common and rare tumor types¹⁻³

Common Types of Cancer That Can Be Caused by *NTRK* Gene Fusion¹⁻²

- ▶ Colon
- Kidney
- Liver
- Lung
- > Skin
- Thyroid
- > And others

Rare Types of Cancer That Can Be Caused by *NTRK* Gene Fusion¹⁻²

- Appendix
- > Brain
- Secretory breast cancer
- > Head and neck
- Salivary gland
- > Soft tissue sarcoma
- Infantile fibrosarcoma (pediatric)
- Congenital mesoblastic nephroma (pediatric)



GETTING TESTED FOR TRK FUSION CANCER

ITRK3) NIRK

NTRK3





There Are Several Different Ways to Test for TRK Fusion Cancer

- Next-generation sequencing (NGS) is considered to be the most complete genomic cancer test. This means that it can detect many genomic alterations at once, rather than one at a time. In some cases, your doctor must request that NTRK gene fusions (involving the genes NTRK1, NTRK2, or NTRK3) are included¹⁻³
- Immunohistochemistry (IHC) is a "staining" technique, a way for doctors and scientists to better see and classify cells under a microscope. IHC uses special proteins known as antibodies to identify the type of cancer. These antibodies will attach only to specific molecules on certain cancer cells, revealing a color change^{4,5}
- Fluorescence in-situ hybridization (FISH) is a test where chromosomes are vividly painted with fluorescent molecules. This helps the doctor see changes that can cause tumors to form and grow. In this test, one alteration lights up at a time⁶
- Reverse-transcriptase polymerase chain reaction (RT-PCR) is a multistep process that uses many copies of a specific DNA segment to find changes in a gene. This process can only detect a limited number of alterations at once^{5,7}

Each test has its own benefits and limitations. Ask your doctor what type of testing is right for you.

References: 1. Su D, Zhang D, Chen K, et al. *J Exp Clin Cancer Res.* 2017;36(1):121. **2.** Lih CJ, Harrington RD, Sims DJ, et al. *J Mol Diagn*. 2017;19(2):313-327. **3.** Rogers T-M, Arnau GM, Ryland GL, et al. *Sci Rep.* 2017;7:42259. doi:10.1038/srep42259. **4.** American Cancer Society. https://www.cancer.org/cancer/non-small-cell-lung-cancer/detection-diagnosis-staging.html. Accessed June 5, 2019. **5.** National Cancer Institute. https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/pathology-reports-fact-sheet. Accessed June 25, 2019. **6.** Cui C, Shu W, Li P. *Front Cell Dev Biol.* 2016;4:89. **7.** Abel HJ, Al-Kateb H, Cottrell CE, et al. *J Mol Diagn*. 2014;16(4):405-417.

TALK TO YOUR DOCTOR ABOUT TESTING

NTRK3

NTRK1

NTRK3





Some Questions You May Want to Ask

- Have I had genomic cancer testing?
- If so, when? What information did it provide about my cancer? Did the test include NTRK gene fusions?
- ▶ If not, would genomic cancer testing help us learn more about my tumor?

The good news is, we are learning more about cancer every day. Genomic cancer testing can help your doctor offer you a more individualized treatment plan that's right for you. Even if you were diagnosed long ago, ask your doctor whether genomic cancer testing could help guide your treatment decisions, now or in the future. Ask your doctor which type of testing is best for you.

RESOURCES FOR YOU, YOUR FAMILY, OR CAREGIVERS

NTRK3

NTRK1

NTRK3



TRKcancer.com

Provides more information about TRK fusion cancer, plus a downloadable checklist to share with your doctor

testyourcancer.com

Offers more knowledge about genomic cancer testing

WHAT YOU SHOULD KNOW

ITRK3) NTRK

NTRK3

NTRK



- Cancer is caused by damaged or changed genes¹
- ✓ Precision medicine is a more personalized approach to help guide cancer care^{2,3}
- ✓ Some patients who get genomic profiling may discover they have a genomic alteration that is linked to an approved or investigational treatment⁴⁻⁶
- ✓ Genomic cancer testing can uncover NTRK gene fusions and other genomic alterations^{7,8}
- ✓ TRK fusion cancer is a type of cancer caused by a change to the NTRK gene⁹⁻¹¹
- ✓ TRK fusion cancer can occur in both rare and common tumor types, in adults and children^{3,9}

If you have questions about TRK fusion cancer or genomic testing, speak to your healthcare provider or visit <u>TRKcancer.com</u>.

References: 1. NIH-National Cancer Institute. https://www.cancer.gov/about-cancer/causes-prevention/genetics. Accessed March 26, 2019. 2. US National Library of Medicine. Genetics Home Reference. https://ghr.nlm.nih.gov/primer/precisionmedicine/definition. Published January 15, 2019. Accessed April 1, 2019. 3. Vaishnavi A, Le AT, Doebele RC. Cancer Discov. 2015;5(1):25-34. 4. Boland GM, Piha-Paul SA, Subbiah V, et al. Oncotarget. 2015;6(24):20099-20110. 5. Massard C, Michiels S, Ferté C, et al. Cancer Discov. 2017;7(6):586-595. 6. Harris MH, DuBois SG, Glade Bender JL, et al. JAMA Oncol. 2016;2(5):608-615. 7. Foundation Medicine. https://www.foundationmedicine.com/genomic-testing. Accessed March 28, 2019. 8. Murphy DA, Ely HA, Shoemaker R, et al. Appl Immunohistochem Mol Morphol. 2017;25:513-523. 9. Amatu A, Sartore-Bianchi A, Siena S. ESMO Open. 2016;1(2):e000023. 10. Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM. Genome Med. 2015;7:129. doi:10.1186/s13073-015-0252-1. 11. Mertens F, Antonescu CR, Mitelman F. Genes Chromosomes Cancer. 2016;55(4):291-310.